• 2010

Company Description

Resolve Therapeutics is focused on developing a novel approach to the treatment of Systemic Lupus Erythematosus (SLE).

Resolve Therapeutics is a private biotechnology company that is dedicated to the goal of improving the lives of patients suffering from lupus. They are focused on the advancement their exciting, novel biologic compound, RSLV-125 from preclinical research through a phase IIa clinical trial. The company is based on the pioneering discoveries made by Dr. Keith Elkon and Dr. Jeff Ledbetter in their laboratories at the University of Washington School of Medicine.